Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sodium valproate crystal form as well as preparation method and application thereof

A technology of sodium valproate and crystal form, which is applied in the field of providing new crystal form II of sodium valproate, which can solve the problems of poor resolubility and reduce the hygroscopicity of sodium valproate, achieve low water content and shorten the dissolution time , good clinical effect

Active Publication Date: 2012-07-25
SICHUAN CREDIT CHEMWERTH PHARMACEUTICAL CO LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In this invention, sodium valproate crystal form III has good solubility, which solves the problem of poor resolubility of existing sodium valproate powder injections, but this patent does not involve research on the hygroscopicity of sodium valproate
[0009] At present, there is no relevant report on reducing the hygroscopicity of sodium valproate by changing the crystal form of sodium valproate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sodium valproate crystal form as well as preparation method and application thereof
  • Sodium valproate crystal form as well as preparation method and application thereof
  • Sodium valproate crystal form as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 The preparation method of sodium valproate crystal form II of the present invention

[0028] Weigh 10 g of sodium valproate, add 66.6 ml of purified water, freeze at -40°C for 18 hours, start the freeze dryer, and dry in vacuum without heating the shelf during the entire drying process to obtain sodium valproate in crystal form II. During the whole drying process, the temperature of the shelf is not raised, that is, the temperature remains constant during the drying process, which ensures a high repeatability of the production method.

[0029] The P-XRD pattern of Form II is shown in figure 1 , see the DSC spectrum figure 2 .

[0030] Wherein, in the X-ray diffraction pattern, there are characteristic absorption peaks at (2θ)=6.40°, 7.22°, 7.40°, 17.05°, 18.25°, 18.98°, 19.27°±0.1° (also can be expressed as 6.40°±0.1°, 7.22°±0.1°, 7.40°±0.1°, 17.05°±0.1°, 18.25°±0.1°, 18.98°±0.1°, 19.27°±0.1°).

[0031] In the present invention, the sodium valproate ra...

Embodiment 2

[0032] Embodiment 2 The preparation method of pharmaceutical composition of the present invention

[0033] Under aseptic conditions, after the sodium valproate crystal form II was prepared by using Example 1, the crystal form II was put into a glass bottle and sealed to obtain the powder injection of sodium valproate crystal form II.

[0034] The beneficial effects of the present invention will be specifically described below through test examples.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a sodium valproate crystal form II as well as a preparation method and application thereof, wherein characteristic absorption peaks appear at diffraction angles of (2theta)=6.3-6.5 DEG, 7.12-7.32 DEG, 7,3-7.5 DEG, 16.95-17.15 DEG, 18.15-18.35 DEG, 18.88-19.08 DEG and 19.17-19.37 DEG in a powder x-ray diffraction pattern of the crystal. The sodium valproate crystal form II provided by the invention has the advantages that the hygroscopicity is significantly reduced and lower water content of the product is guaranteed to ensure that the quality of the sodium valproate is more stable in storage period; while the hygroscopicity is reduced, the dissolution time of the product is significantly shortened and the dissolvability of the product is improved to ensure that the curative effect and very good safety of the sodium valproate are guaranteed in clinical application, the injection pain is also significantly relieved, compliance of patients is increased during treatment and very good clinical effect of the treatment is obtained.

Description

technical field [0001] The invention provides a new crystal form II of sodium valproate, which belongs to the field of medicine. Background technique [0002] Sodium valproate is a first-line broad-spectrum antiepileptic drug. The chemical structural formula is as follows: [0003] [0004] The chemical name of sodium valproate is 2-sodium valproate, molecular formula: C 8 h 15 NaO 2 , with a molecular weight of 166.2, is a white, odorless, crystalline water-soluble powder. It is a better antiepileptic drug and is suitable for various epilepsy (petit mal seizures, focal epilepsy, psychomotor seizures and mixed seizures) and Prevention and treatment of personality and behavioral disorders caused by epilepsy [Chinese Journal of Pharmaceutical Industry 1999, 30(9): 389-390], which can be prepared into oral preparations and injection preparations. At present, the specifications of oral preparations include tablet: 100mg, 200mg, syrup: 5ml: 200mg, 500mg. Sodium valproate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C53/128C07C51/43A61K31/19A61P25/08
Inventor 傅霖李文婕陈刚陈功政万树伦
Owner SICHUAN CREDIT CHEMWERTH PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com